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Abstract
Objective—Determine the frequency, time-to-flare, and predictors of disease flare upon 
withdrawal of anti-tumor necrosis factor (TNF) therapy in children with polyarticular forms of 
juvenile idiopathic arthritis (PF-JIA) who demonstrated ≥ 6 continuous months of clinical inactive 
disease (CID).
Methods—In 16 centers 137 patients with PF-JIA in CID on anti-TNF therapy (42% of whom 
were also on methotrexate [MTX]) were prospectively followed. If CID was maintained for the 
initial 6 months on study anti-TNF was stopped and patients assessed for flare at 1, 2, 3, 4, 6, and 
8 months. Life-table, t-tests, Chi square, and Cox regression analyses were used to identify 
independent variables that could significantly predict flare by 8 months or time-to-flare.
Results—106/137 (77%) maintained CID on anti-TNF therapy for the initial 6 months and were 
included in the phase of the study in which anti-TNF therapy was stopped. Stopping anti-TNF 
resulted in disease flare in 39/106 (37%) patients by 8 months. The mean/median time-to-flare 
were 212/250 (SEM 9.77) days. Patients with shorter disease duration at enrollment, older age at 
onset and diagnosis, shorter disease duration prior to experiencing CID, and shorter time from 
onset of CID to enrollment were found to have significantly lower hazard ratios (p< 0.05) for 
likelihood of flare by 8 months.
Conclusion—Over one-third of patients with PF-JIA in sustained CID will flare by 8 months 
following discontinuation of anti-TNF therapy. Several predictors of lower likelihood of flare were 
identified.
Current treatment approaches for children with polyarticular forms of juvenile idiopathic 
arthritis (PF-JIA) (1) have resulted in up to 50% of the patients demonstrating clinical 
inactive disease (CID) (2) while on treatment (2–13). Much of the success in inducing CID 
is due to the introduction of anti-tumor necrosis factor alpha (anti-TNF) biologic therapies 
used early in the treatment of a large proportion of children with JIA (4–8, 12, 13, 15). Anti-
TNF therapy has known short- and medium-term toxicities in children with JIA; the long-
term toxicities (>15 years) are unknown, and the medication cost is substantial (5, 13, 16–
24). Prediction of which children with JIA on anti-TNF therapies in CID can discontinue 
therapy without experiencing a recurrence of clinically active disease is presently limited to 
retrospective or small prospective cohort studies and studies of proposed biomarkers (25–
29). Studies describing which patients may safely discontinue treatment once CID is 
achieved have not been fully validated (30, 31).
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The objective of this research was to determine the time-based risk of disease flare in 
patients with polyarticular forms of JIA (PF-JIA) (rheumatoid factor [RF] positive or 
negative and extended oligoarticular) who had experienced sustained CID at the time anti-
TNF therapy was withdrawn. Secondary objectives included (1) the identification of clinical 
and demographic variables that impact time to and risk of flare, and (2) the impact of 
background methotrexate (MTX) on time-to flare and risk of flare after withdrawal of anti-
TNF therapy.
PATIENTS AND METHODS
Study Design and Patient Flow
This multi-center, prospective study had 2 phases conducted over a 14 month, on-protocol 
period. In the first 6-month phase patients who were in a state of CID were enrolled and 
continued an anti-TNF agent and background drugs (if applicable). If CID was maintained 
for the initial 6 months of the study, the patient became eligible for the second phase during 
which anti-TNF therapy was withdrawn while background medications were held stable. 
TNF withdrawal was done by protocol in all sites and in all instances anti-TNF therapy was 
discontinued completely at the month 6 study visit and not tapered. These ‘evaluable 
patients’ returned for study visits at 1, 2, 3, 4, 6 and 8 months to determine if their disease 
had flared according to pre-specified criteria (see below for definition). The protocol did not 
specify ‘study visit windows’ outside of which data would be discarded. While greater than 
90% of visits occurred within 2 weeks of the expected study date, some were outside this 
span. These data were used in the analysis resulting in the maximal follow-up after stopping 
the anti-TNF agent being up to 8 months in 67 patients and >8 but ≤10 months in 39 
patients.
The study was approved by the Institutional Review Board (IRB) at each participating site 
and was conducted to be in compliance with the Helsinki Declaration (http://
www.wma.net/en/20activities/10ethics/10helsinki/index.html). Parent/patient consent 
(assent, if appropriate) and screening for eligibility were done at the participating site at 
which the patient was recruited. Each patient’s eligibility was validated via eligibility case 
report forms immediately sent to the Pediatric Rheumatology Collaborative Study Group 
(PRCSG) Coordinating Center (CC) at Cincinnati Children’s Hospital Medical Center. The 
CC served as the clinical research organization for this study and oversaw all matters related 
to regulatory, financial, and clinical affairs, as well as data management, quality assurance, 
and analysis.
An independent data safety and monitoring board (DSMB) appointed by the National 
Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases 
(NIH/NIAMS) monitored all aspects of the study including recruitment and retention rate, 
modifications to the protocol and/or changes to the case report forms, and any concerns 
regarding patients’ overall well-being and safety. An initial DSMB meeting was held prior to 
study initiation to resolve outstanding issues. Following study startup, and for the first 2 
years of enrollment, the DSMB met with all CC personnel via teleconference every 3 
months. The teleconferences were conducted using a standardized protocol for DSMB 
meetings. As the study progressed, teleconferences were less frequent unless problems 
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arose. The only problem resulting in an ad hoc DSMB meeting was slow patient enrollment. 
The DSMB members played an active, collaborative role in addressing enrollment issues 
and successfully advocated for increased and extended funding for the study from the NIH.
Patients were recruited from tertiary pediatric rheumatology centers in the United States 
beginning in July 2009. Prior to the start of patient recruitment, a face-to-face investigators’ 
meeting was held with all original study sites in attendance. New sites were added as the 
study progressed to increase the rate of enrollment. Personnel at new sites underwent 
identical training to that presented at the investigators’ meeting during an on-site visit by the 
study principal investigator (DJL).
Outcomes
The primary outcome for this study was disease flare using a variation of the validated 
criteria defined as 30% worsening in 3 or more of any of the 6 JIA American College of 
Rheumatology (ACR) core set variables (32), with no more than 1 improving by >30% (33). 
The 6 core set variables include the physician’s global assessment of disease activity 
(PhGA)(VAS 0–10, 0 = inactive disease), parent/patient assessment of overall well-being 
(PaGA) VAS 0–10, 0 = best well-being), functional ability measured by the Childhood 
Health Assessment Questionnaire (CHAQ), the number of joints with active arthritis (using 
the ACR definition of “active joint) (32), the number of joints with limitation of motion, and 
an acute phase reactant (ESR was used in this study). Because enrolled subjects began the 
second phase in CID so that most of the core set variables were normal or 0, a 30% 
worsening could represent a less than clinically important change. Thus, in this study, to be 
considered to have flared on a particular parameter, the patient had to worsen by at least 
30% and also demonstrate a minimum change of the following amounts: PhGA or PaGA 
increase by at least 2 units on a 21 circle 0–10 unit VAS (34), increase in the active joint 
count or joints with limited motion count by at least 2 joints, an increase by a minimum of 
+0.125 on the CHAQ (validated minimally clinically important difference) (35), and an 
increase in the ESR from normal to abnormal. If a patient demonstrated active uveitis they 
were considered to have “flared”.
CID was defined using the ACR Provisional Criteria (2) for CID in JIA and includes the 
following: no joints with active arthritis (using the ACR definition of “active joint”)(32), no 
fever, rash, serositis attributable to JIA, no active uveitis (as per most recent exam by an 
ophthalmologist), an ESR ≤ the upper limit of the normal range for the assay used at the site 
(ESR could be elevated and the patient still be considered in CID if the elevation was not 
attributable by the treating physician to JIA), PhGA ≤ to 0.5 on a 21 circle 0–10 unit VAS, 
and duration of morning stiffness ≤15 minutes. “Clinical remission on medications” also 
used the ACR Provisional Criteria and required CID to be met for 6 continuous months.
Inclusion/Exclusion criteria
To be eligible for enrollment into the initial 6-month phase, subjects had to be between 4 and 
20 years of age with a diagnosis of polyarticular (both rheumatoid factor positive and 
negative) or extended oligoarticular JIA (1) and be in a state of CID while receiving 
etanercept, adalimumab, or infliximab. All Food and Drug Administration (FDA) label 
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exclusions for anti-TNF therapy had to be absent, a history of regular slit-lamp exams as 
recommended by the American Academy of Pediatrics guidelines (36) had to be present, 
and the hemoglobin had to be ≥10 g/dL at baseline. Females of childbearing potential and 
males who had reached puberty had to agree to use adequate contraception or abstinence 
during the study. An IRB-approved consent (and assent if applicable) had to be signed. 
Exclusion criteria included diagnosis with other categories of JIA, previous treatment with 
rituximab, concurrent treatment with any other biologic agent, or corticosteroids >0.2 
mg/kg/d or >10 mg/d (whichever is less). Patients with a diagnosis of any other 
inflammatory, acute or chronic illness that might affect laboratory results or ability to 
discontinue anti-TNF biologic therapy were excluded.
Allowable treatments
Anti-TNF therapies allowed during the first 6 months of study included etanercept (ETN), 
infliximab (IFX), and adalimumab (ADA). The choice of which anti-TNF was used was at 
the discretion of the examining physician. Dosing and method of administration followed 
recommended guidelines. Patients were permitted to receive stable background therapy with 
NSAIDs, MTX, other DMARDs (except rituximab) and low dose corticosteroids 
(prednisone dose ≤0.2 mg/kg/d or ≤10 mg/d, whichever was less). All background therapies 
for JIA were to remain unchanged from the time of enrollment until the final study visit or 
discontinuation from study.
Data Management, Sample Size and Statistical Methods
Case report forms were sent from participating sites, via fax, to the study coordinating center 
(CC) where forms underwent real-time quality control procedures as all data required for the 
determination of “flare” had to be collected, verified and analyzed before the end of the 
study visit before any treatment changes were made. Additional data requests were issued if 
necessary. All data were stored, managed, and analyzed using Red Cap, Microsoft Excel, 
and SAS (Version 9.3TS), respectively.
Sample size estimation accommodated the following possibilities: (a) background MTX 
therapy may affect frequency of disease flare, (b) not all subjects enrolled in the study will 
exhibit persistent CID for the initial 6 months (and thus will not be in the part of the 
withdrawal phase), and (c) some patients will become lost-to-follow-up due to reasons 
beyond the control of investigators. We anticipated 102 evaluable patients would be 
necessary to test the hypothesis that 60% of patients would experience disease flare within 8 
months of discontinuation of anti-TNF therapy, assuming half of whom would be on MTX. 
To attain enough evaluable patients, with an anticipated drop-out/non-evaluable rate of 15%, 
we estimated that 118 patients would need to be enrolled to meet statistical power 
requirements of 80%. The sample size was calculated to address the specific aims of the 
grant, one of which included the diagnostic ability of biomarkers. The sample size was 
calculated using the method described in Obuchowski and McClish (37).
Descriptive statistics were used to summarize medications, demographic and disease 
characteristics at baseline and 6 months. Kaplan-Meier survival curves were generated to 
estimate rate of flare over time following anti-TNF withdrawal for the study population and 
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stratified by covariates, including type of anti-TNF agent used (ADA, ENB, INF), JIA 
category (extended oligoarticular, RF+ polyarticular, RF− polyarticular) and background 
MTX use (yes/no). Likelihood ratios and Chi square statistics were used to compare the 
survivorship functions among groups. Multivariable logistic analysis was used to model risk 
of flare (yes/no). Cox regression analyses were employed to assess predictors of time-to-
flare. Hazard ratios (HR) were calculated to identify potential independent predictors of flare 
by 8 months. Stepwise selection procedures were used where variables with P values <0.25 
from univariable analysis were entered in the multivariable analysis and only those 
significant at P<0.05 were retained. Interaction terms that were clinically meaningful were 
also considered. The interactions we considered were: MTX by TNF, JIA subtype by gender, 
and JIA subtype by age. The final model only retains the MTX by TNF interaction.
Some variables, such as the age and time duration variables, are known to be collinear. 
Entering all these variables in the same regression equation would cause collinearity issues. 
We selectively entered variables and avoided those that were derived from an already entered 
variable. In addition, some nonderived variables may present strong correlations with other 
variables in the model. To address this issue, we used the ridge option in the logistic 
regression procedure (38), which helps stabilize the regression estimate. For some variables 
in the regression analysis, the model suffers from very small cell size. The Firth option was 
used in the analysis to address this issue (39).
Biospecimens
Blood was drawn on each subject at baseline and at various follow-up visits for purposes of 
genetic, gene expression and translational studies. The results of these studies are to be 
reported elsewhere.
RESULTS
Sixteen tertiary pediatric centers in the US enrolled a total of 137 patients who met the 
eligibility criteria. Review of the prescreening logs indicated that 137/147 (93.1%) eligible 
subjects screened were enrolled. Data were locked for this analysis in August 2014. 
Demographic, disease and pharmacological treatments of the enrolled population are given 
in Table 1. One subject received an additional non-biologic DMARD (hydroxychloroquine) 
and one other subject received corticosteroids. Seven of 137 subjects (5.1%) had been 
treated with another biologic in the 6 months prior to the baseline visit. Four of the 137 
(2.9%) had a history of uveitis. Slit lamp exams, as per Academy of Pediatric guidelines 
(36), were required before and during the study. Uveitis status was part of the CID 
definition. Three of 137 (2.2%) lost CID status due to a flare of uveitis.
Patient disposition
Figure 1 provides a graphical summary of outcome of all enrolled patients. Seven (5%) of 
the 137 enrolled patients dropped out during the first 6 months (6 due to being lost to 
follow-up or non-compliance, 1 due to a change in JIA category). Of the remaining 130, 24 
(18.5%) did not remain in clinical remission on medications, i.e., maintain CID for the first 6 
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months, despite stable anti-TNF and background medications. Thus, a total of 106 (77.4% of 
the total enrolled) were considered ‘evaluable’ and entered the second phase of the study.
Demographic, disease and therapeutic characteristics of those unable to maintain CID for 
6 months while on therapy
Overall, demographic, and disease characteristics of those not evaluable (not able to 
maintain CID for the first 6 months) were not significantly different than the evaluable (able 
to maintain CID for the first 6 months) group at study enrollment with the following 
exceptions (Table 2). Males (p = 0.04) were more likely and those with positive RF were less 
likely (p = 0.04) to experience clinical remission on medications for the first 6 months. Type 
of anti-TNF agent was significantly associated (p = 0.04) with those on etanercept the most 
likely to experience continuous CID for the first 6 months. Perhaps this is due to etanercept 
being more likely to be the initial anti-TNF agent used. In the extended oligoarticular group, 
6% (1/18) were unable to maintain CID for 6 months, as were 18% (19/102) in the Poly RF– 
and 40% (7/17) in the Poly RF+ categories (Fisher’s exact, p= 0.04). ANA status and MTX 
use were not associated with the ability to maintain CID prior to treatment withdrawal (Chi-
square p values; 0.48, 0.14, respectively).
Disease Flare/No Flare by 8 months
Sixty-seven of 106 patients (63%) completed the 8-month phase without experiencing flare. 
Although the definition of “flare” did not contain either “systemic manifestations” (related 
to systemic form of JIA) or uveitis these were tracked prospectively at each study visit. No 
patient demonstrated “systemic manifestations”, which is not surprising, as systemic JIA 
patients were excluded. Three patients demonstrated uveitis flare during the study and, if 
this occurred during the time after stopping anti-TNF therapy, they were declared “flared” 
and removed from the study. The mean/median time-to-flare was 212/250 days and the 
standard error of the mean (SEM) was 9.8 days. Table 3 presents demographic, disease and 
therapeutic characteristics for those who flared and those who did not by 8 months. Older 
age at disease onset, older age at diagnosis and shorter disease duration were significantly 
associated with a lower risk for disease flare.
Table 3 shows hazard ratios using univariable Cox regression time-to-event analyses and 
associated significance levels. Five variables were found to be significantly associated with 
likelihood of flare by 8 months. Later age of onset and diagnosis, shorter disease duration at 
enrollment in the study, and shorter time from disease onset until first occurrence of CID 
were significant predictors of decreased risk for flare. Longer duration of CID prior to anti-
TNF agent discontinuation was a significant predictor of increased risk of flare. Thus, some 
variables may help to predict risk of flare based on Cox regression analysis. Supplemental 
Table 1 compares those who either failed to maintain CID in the first 6 months or flared 
within the 8 months off anti-TNF therapy to those who were able to both maintain CID in 
the first 6 months and did not flare within 8 months off anti-TNF therapy. No variables were 
statistically different in comparing these 2 groups.
Table 4 provides the number of patients who flared and rate of flare at various study visits 
for each stratum of independent variables. Because of logistical difficulties in returning 
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children to clinic for study visits on an exact date, end-of-study visit occurred later than 8 
months but ≤10-month follow-up period in 39 patients. Using life-table analyses, no 
significant differences were found in flare rates between any strata of any variable. However, 
stepwise logistic regression identified older age at diagnosis (OR=1.14., 95%CI 1.02–1.26) 
and use of MTX in those on adalimumab (OR 34.12, 95%CI 1.40–829.8)) as the only 
significant predictors of decreased risk of flare over the 8 months following discontinuation 
of TNF. The area under the receiver operating characteristic (ROC) curve was 0.696, 
indicating fair accuracy in predicting flare (37). The stepwise Cox regression found the same 
set of predictors: HR = 1.10 (1.01, 1.20) for older age HR =11.6 (1.20, 112.78) for use of 
MTX among those patients treated with adalimumab (note the large confidence interval for 
this last HR due to few patients in this group, this likely represents Type 2 error).
Figure 2A provides a Kaplan-Meier (K-M) curve showing the probability of flare among all 
evaluable patients throughout the 8-month phase. As mentioned above, because of logistical 
difficulties, one end-of-study visit occurred later than 8 months (10 months). Mean time to 
flare was 7.01 months (SEM 0.32) with a median of 8.26 (95%CI 7.80– 8.66) months. 
Figures 2B–2D present survival curves using 3 independent variables that had been 
hypothesized to predict flare rate and time-to-flare (± MTX, anti-TNF agent given prior to 
discontinuation of therapy, and subtypes of JIA). None of these variables proved to be 
statistically significant predictors of either likelihood of flare or time-to-flare.
DISCUSSION
In this study, several new and clinically relevant observations were made about stopping 
anti-TNF therapy in patients with PF-JIA in CID. CID was an unstable state and 18.5% of 
the patients were unable to maintain CID for 6 continuous months of observation, even 
while continuing to receive the anti-TNF agent and stable doses of all background 
medications. This was especially true for the RF+ polyarthritis group. Unlike the studies of 
stopping MTX (in the absence of anti-TNF therapy), the duration of CID at the time of 
stopping the anti-TNF therapy was significantly related to likelihood of flare. In studies 
examining the effect of discontinuing MTX, CID durations of 6, 12 and 18 months all 
resulted in a similar flare rate of approximately 50% (40, 41). However, in this study there 
was an increased risk of disease flare for longer duration of CID. These data certainly do not 
support the existence of a protective effect of longer duration of CID before considering 
stopping anti-TNF therapy. In fact, the data suggest that CID, even in those who did 
demonstrate CID consistently for the first 6 months of the study, continued to be an unstable 
clinical state and prolonged observation of CID resulted in a significantly greater risk for 
flare.
Our results are in line with a growing literature suggesting that there is a “window of 
opportunity” early in the treatment of JIA that supports early introduction of aggressive 
therapy and rapid achievement of CID will result in better long-term control of JIA and 
improved outcomes (4, 42–44). In a secondary analysis of the TREAT JIA trial data (4), the 
duration of disease prior to initiation of aggressive therapy was significantly inversely 
associated with ability to realize CID on aggressive therapy. For each month less of disease 
duration prior to initiating aggressive therapy, the likelihood of reaching CID was increased 
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by 1.7-fold. In this study, longer duration of disease prior to first achieving CID was 
significantly associated with a decreased ability to maintain CID after stopping the anti-TNF 
agent.
The major strength of this study is that the study subjects were followed prospectively by 
protocol and all assessments and determinations of disease status (CID, flare/no flare) were 
done with real time assessment centrally at the study coordinating center. In addition, 137 of 
the 147 eligible subjects screened (93.1%) were enrolled. However, this study also has 
limitations. Perhaps the largest short coming is that we do not capture the difficulty in 
regaining CID among those who flared. This shortcoming will be addressed in a paper 
describing the longer follow-up of this cohort. The study population was small and not 
population-based. The patients were all recruited from academic pediatric rheumatology 
centers, which may have introduced a selection bias for patients with more severe disease. If 
patients with milder disease were enrolled then, perhaps, the flare rate would have been 
lower. The proportion flaring was smaller than predicted in the preliminary power analysis 
further limiting power. The protocol did not specify ‘study visit windows’ outside of which 
data would be discarded. While greater than 90% of visits occurred within 2 weeks of the 
expected study date, some were outside this span. These data were used in the analysis. 
Estimation of the exact time-to-flare is challenging. Flares could only be determined by the 
examining physician and, therefore, could only occur at study visits. Thus, it is possible that 
some patients flared before their study visit. However, unscheduled study visits were 
performed and actual time of study visit was used in the data analysis for patients that were 
more symptomatic.
Despite the tremendous potential in JIA for the use of biomarker panels to determine exactly 
who is the best candidate for a therapy, and which therapy is more likely to induce 
remission, biomarker studies have yet to produce a validated assay (31). However, studies of 
serum levels of S100 A8/A9 have demonstrated good to excellent ability (sensitivity 100%, 
specificity 70%) to predict flares in JIA patients stopping methotrexate therapy (41). The 
predictive ability of S100 A8/A9 and S100 A12 has been studied in samples collected in this 
study and submitted in a companion manuscript to this journal. Increasingly, ultrasound and 
MRI are being used to assess JIA patients in CID. However, the few studies of the ability of 
ultrasound to predict flare in JIA patients in CID have provided conflicting results (45, 46). 
The predictive ability of MRI findings in JIA patients in CID has not been assessed.
A central issue in study design was which of several published definitions of flare to use. We 
considered but eventually choose to not use the definition used in the Foell manuscript (41) 
in which worsening in any one of the selected parameters was considered a disease “flare”. 
A multifactored definition of flare was selected to provide enough rigor in the degree of 
worsening to avoid the visit to visit minor variation in disease activity and to minimize the 
effect of the “noise” in the individual assessment measures which is especially influential in 
low disease activity states. We wanted the ‘flare” definition to represent enough worsening 
that it would likely result in a need for a change in systemic JIA therapy and not just a minor 
adjustment or injection of 1–2 joints. The definition chosen was also one that had been 
formally validated in a methodologic paper (33) and field tested in clinical trials (5, 9, 10, 
16)).
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In conclusion, we offer the following observations that may be informative for the clinical 
care of children with JIA. In this prospective study of children with PF-JIA who achieve 
CID while on anti-TNF therapy recruited from the population of patients routinely seen in 
pediatric rheumatology centers, CID is an unstable condition in about one-fifth of patients. 
Following discontinuation of the anti-TNF agent in those who did achieve clinical remission 
on medications, the mean time-to-flare was about 7.0 months, and by 8 months over a third 
will have flared. The data do not support the effectiveness in continuing background MTX in 
those who do stop anti-TNF therapy as a method to decrease the risk of flare. Longer 
duration of CID prior to stopping anti-TNF therapy was associated with an increased risk for 
flare and thus does not support the perception that longer maintenance of anti-TNF therapy 
as supportive of decreased risk for flare in those who have already achieved at least 6 
months of CID.
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Figure 1. 
Patient Disposition.
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Figure 2. 
Kaplan-Meier Curves by 8 months of prospective observation in patients in JIA patients in 
clinical inactive disease (CID) who withdrew anti-TNF therapy. Patient visits were censored 
at 8 months follow-up even though some patients were followed longer than 8 months. 
Figure A shows the flare rate in the overall population who withdrew therapy. Figure B 
shows comparison of flare rates in those with and without background methotrexate therapy. 
Figure C shows comparison of flare rates of several types of anti-TNF therapy. Figure D 
shows flare rates of various JIA categories.
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Table 1
Demographic, Disease and Treatment Characteristics of the Study Population at Enrollment.
All patients (N = 137) N (%)
Race
 Caucasian 129 (94)
 African American 7 (5)
 Asian 1 (1)
Gender
 Female 102 (74)
 Male 35 (26)
ANA (3 unknown)
 Positive 65 (48)
 Negative 69 (50)
Rheumatoid Factor (RF) (3 unknown)
 Positive 17 (12)
 Negative 117 (85)
JIA Category
 Extended oligo 18 (13)
 RF positive poly 17 (12)
 RF negative poly 102 (75)
Anti-TNF treatment
 Etanercept 106 (77)
 Adalimumab 25 (18)
 Infliximab 6 (5)
Background MTX
 Yes 57 (42)
 No 80 (58)
Mean (median) Range
Age (yrs) 11.3 (11.6) 3.4 – 20.1
Age at onset (yrs) 6.2 (5.0) 0.7– 16.9
Age at diagnosis (yrs) 6.7 (5.8) 1.0 – 17.6
Disease duration (yrs) 5.0 (3.9) 0.6 – 18.6
Age, first occurrence of CID (yrs) 10.1 (10.0) 2.5 – 18.6
Time from onset to first CID (yrs) 3.9 (2.7) 0.3 – 14.8
Time from first CID to enrollment into study (yrs) 1.1 (0.5) 0.0 – 12.1
MTX dose (mg/kg/wk) 0.44 (0.40) 0.1 – 1.02
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Table 2
Demographic and Disease Characteristics of All Enrolled Patients Comparing Patients who failed to maintain 
Clinical Inactive Disease in the First 6 months (“Not evaluable”) to those maintained CID for the First 6 
Months (“Evaluable”).
All Patients Not evaluable Evaluable P value**
No (%) No. (%) * No. (%)*
Total 130 (100%) 24 (18%) 106 (82%) --
Gender 0.03
Females 97 (75%) 22 (92%) 75 (71%)
Males 33 (25%) 2 (8%) 31 (29%)
Race 0.38
Caucasian 122 (94%) 24 (100%) 98 (92%)
African American 7 (5%) 0 7 (7%)
Asian 1 (1%) 0 1 (1%)
JIA Diagnosis 0.04
Extended oligo 18 (14%) 1 (4%) 17 (16%)
RF positive poly 15 (11%) 6 (25%) 9 (8%)
RF negative poly 97 (75%) 17 (71%) 80 (75%)
ANA status (N = 103) 0.39
Positive 63 (50%) 10 (42%) 53 (51%)
Negative 64 (50%) 14 (58%) 50 (49%)
RF status (N = 104) 0.02
Positive 15 (12%) 6 (26%) 9 (9%)
Negative 112 (88%) 17 (74%) 95 (91%)
Concurrent MTX 0.16
Yes 54 (42%) 13 (54%) 41 (39%)
No 76 (58%) 11 (46%) 65 (61%)
Anti-TNF agent 0.04
etanercept 101 (78%) 14 (58%) 87 (82%)
adalimumab 22 (17%) 8 (33%) 14 (13%)
infliximab 7 (5%) 2 (8%) 5 (5%)
Mean (std) Mean (std) Mean (std) P value***
Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3)
Age at enrollment (yrs) 11.16 (4.48) 11.13 (4.39) 11.16 (4.52) 0.98
11.49 (6.79, 14.77) 10.8 (7.69, 14.98) 11.65 (6.68, 14.72)
Age at disease onset (yrs) 6.05 (4.57) 6.21 (4.50) 6.01 (4.61) 0.85
4.48 (2.01, 9.74) 4.64 (2.25, 9.79) 4.24 (2.00, 9.70)
Age at diagnosis (yrs) 6.58 (4.65) 6.92 (4.68) 6.5 (4.67) 0.69
5.4 (2.44, 10.21) 5.78 (2.73, 10.93) 5.33 (2.34, 10.21)
Disease duration at enrollment (yrs) 5.11 (3.81) 4.75 (3.84) 5.18 (3.82) 0.63
3.89 (2.28, 6.51) 3.72 (2.06, 5.54) 3.98 (2.39, 6.56)
Age, first occurrence of CID (yrs) 10.02 (4.61) 9.73 (4.42) 10.09 (4.67) 0.73
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Mean (std) Mean (std) Mean (std) P value***
Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3)
9.94 (6.27, 13.97) 9.09 (6.28, 14.36) 10.13 (6.27, 13.87)
Time from disease onset to first occurrence of CID (mos) 3.94 (3.44) 3.32 (3.37) 4.08 (3.45) 0.34
2.68 (1.48, 5.36) 2.29 (1.49, 3.46) 2.88 (1.47, 5.8)
Time from first occurrence of CID to baseline (yrs) 1.15 (1.77) 1.40 (1.91) 1.10 (1.74) 0.45
0.48 (0.18, 1.49) 0.50 (0, 2.35) 0.48 (0.19, 1.45)
Duration of anti- TNF (yrs) 2.48 (1.81) 2.12 (1.60) 2.55 (1.84) 0.33
1.87 (1.30, 3.09) 1.70 (1.05, 2.74) 1.9 (1.32, 3.09)
MTX dosage (mg/kg) 0.44 (0.21) 0.39 (0.24) 0.46 (0.20) 0.28
0.42 (0.27, 0.60) 0.26 (0.24, 0.51) 0.47 (0.30, 0.60)
*
Patients “who failed” includes both those who were unable to maintain clinical inactive disease in first 6 months and those who flared within 8 
months after stopping anti-TNF therapy; those who “did not fail” includes only those who maintained clinical inactive disease for first 6 months 
and did not flare for 8 months after stopping anti-TNF therapy.
**
P value based upon Chi square comparison of number who flared vs. not flared between strata of individual variables.
***
P value based upon Student T test comparison of group means between two columns
Note: 3 ANA results unknown; 2 RF results unknown (in order to be included in the analysis the 2 patients with unknown RF results were 
considered to be RF (−); One Age at first occurrence of CID value unknown.
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Table 3
Hazard Ratio Estimates for Univariable Predictor Variables from Cox Regression Analyses of Time to Flare 
(N = 106 unless otherwise indicated).
Hazard Ratio (CI) P Value
Gender (Female vs. Male) 1.24 (0.61, 2.55) 0.55
JIA Diagnosis (Extended Oligo vs. Poly RF−) 1.33 (0.611, 2.91) 0.47
JIA Diagnosis (Poly RF+ vs. Poly RF−) 0.25 (0.04, 1.86) 0.17
ANA (Negative vs. Positive) 0.76(0.39, 1.46) 0.4
RF (Negative vs. Positive) 1.96 (0.47, 8.15) 0.86
Methotrexate (no vs yes) 1.25 (0.64, 2.44) 0.51
Anti-TNF (infliximab vs. adalimumab) 0.39 (0.09, 1.78) 0.23
Anti-TNF (etanercept vs. adalimumab) 0.52 (0.16, 1.14) 0.29
Age at enrollment (yrs) 1.00 (0.93, 1.08) 0.97
Age at onset (yrs) (n =105) 0.92 (0.85, 0.99) 0.03
Age at diagnosis (yrs) 0.91 (0.84, 0.99) 0.02
Disease duration at enrollment (mos) (n = 105) 1.12 (1.04, 1.21) <0.01
Age, first occur of CID (yrs) (n = 105) 0.98 (0.91, 1.05) 0.48
Time from disease onset to first CID (mos)(n=105) 1.10 (1.01, 1.20) 0.03
CID duration, first occurrence to enrollment (mos) 1.16 (1.01, 1.33) 0.04
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Table 4
Life Table Analyses of Time to Flare after withdrawal of anti-TNF
Analysis was divided into two intervals (0–4 mos and 4–10 mos) to accommodate that some patients were 
seen up to 10 months after stopping anti-TNF therapy.
(0–4) month
Flare/Effect Sample Size 
(Rate of Flare±SE)
(4–10) month
Flare/Effect Sample Size (Rate of Flare±SE)
P value
All 25/106 (23.5±0.04) 14/50.5 (27.7 ±0.06)
Gender 0.55
 Females 20/75 (26.7±0.05) 9/34.5 (26.1 ± 0.07)
 Males 5/31 (16.1±0.07) 5/16 (31.2 ± 0.12)
Race 0.30
 Caucasian 24/98 (24.5±0.04) 14/47 (29.8 ± 0.07)
 African American 1/7 (14.3±0.13) 0/3 (0 ±0)
 Asian 0/1 (0±0) 0/0.5 (0 ±0)
JIA Diagnosis 0.12
 Extended oligo 6/17 (35.3±0.12) 2/7 (28.6 ± 0.17)
 RF positive poly 1/9 (11.1±0.10) 0/5.5 (0 ±0)
 RF negative poly 18/80 (22.5±0.05) 12/38 (31.6 ± 0.08)
ANA status (N = 103) 0.37
 Positive 12/53 (22.6±0.06) 10/26 (38.5 ± 0.10)
 Negative 12/50 (24±0.06) 3/23 (13 ±0.07)
RF status (N = 104) 0.26
 Positive 1/9 (11.1±0.10) 1/5.5 (18.2 ± 0.16)
 Negative 24/95 (25.3±0.04) 12/43.5 (27.6 ± 0.07)
Concurrent MTX 0.47
 Yes 10/41 (24.4±0.07) 3/17.5 (17.1 ± 0.09)
 No 15/65 (23.1±0.05) 11/33 (33.3 ± 0.08)
Anti-TNF agent 0.36
 etanercept 21/87 (24.1±0.05) 11/41 (26.8 ± 0.07)
 adalimumab 3/14 (21.4±0.11) 1/6.5 (15.4 ± 0.14)
 infliximab 1/5 (20.0±0.18) 2/3 (66.7 ± 0.27)
Age at enrollment (yrs): 0.68
 ≤ median 13/44 (29.6±0.07) 4/18 (22.2 ± 0.10)
 > median 12/62 (19.4±0.05) 10/32.5 (30.8 ± 0.08)
Age at onset (yrs) (N=105): 0.03
 ≤ median 17/54 (31.5±0.06) 8/23.5 (34.0 ± 0.10)
 > median 8/51 (15.7±0.05) 6/26.5 (22.6 ± 0.08)
Age at diagnosis (yrs): 0.02
 ≤ median 17/50 (34.0±0.07) 7/21 (33.3 ± 0.10)
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(0–4) month
Flare/Effect Sample Size 
(Rate of Flare±SE)
(4–10) month
Flare/Effect Sample Size (Rate of Flare±SE)
P value
 > median 8/56 (14.3±0.05) 7/29.5 (23.7 ± 0.08)
Disease duration at enrollment (yrs, N = 105) 0.20
 ≤ median 0/2 (−) 0/1 (−)
 > median 25/103 (24.3±0.04) 14/49 (28.6 ± 0.06)
Age, first occurrence of ID** (yrs, N = 105) 0.14
 ≤ median 6/21 (28.6±0.10) 5/10 (50.0 ± 0.16)
 > median 19/84 (22.6±0.05) 9/40 (22.5 ± 0.07)
Time from disease onset to first occurrence of 
ID (mos, N = 105)
0.06
 ≤ median 2/16 (12.5±0.08) 1/8 (12.5 ± 0.12)
 > median 23/89 (25.8±0.05) 13/42 (31.0 ± 0.07)
Time from first occurrence of ID to baseline 
(yrs, N=105)
0.04
 ≤ median 10/53 (18.8±0.05) 5/26 (19.2 ± 0.08)
 > median 15/52 (28.9±0.06) 9/24 (37.5± 0.10)
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